Provided by Tiger Trade Technology Pte. Ltd.

Accendra Health Inc

0.2031
-0.0950-31.87%
Post-market: 0.21500.0119+5.86%19:55 EST
Volume:2.90M
Turnover:616.07K
Market Cap:15.62M
PE:-0.05
High:0.2450
Open:0.2442
Low:0.2005
Close:0.2981
52wk High:4.69
52wk Low:0.1910
Shares:76.90M
Float Shares:56.17M
Volume Ratio:0.33
T/O Rate:5.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9457
EPS(LYR):-14.3179
ROE:-198.35%
ROA:0.69%
PB:-0.03
PE(LYR):-0.01

Loading ...

Press Release: Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call

Dow Jones
·
Oct 23

Accendra Health Publishes Update to Financial Calendar

Reuters
·
Oct 23

Accendra Health Gets NYSE Notice After 30-Day Average Share Price Falls Below $1

Reuters
·
Oct 10

Accendra Health Receives Continued Listing Standard Notice from Nyse; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard

THOMSON REUTERS
·
Oct 10

Bank of America Corp Reports 10.8% Passive Stake in Accendra Health as of Sept 30 - SEC Filing

THOMSON REUTERS
·
Oct 07

Accendra Health Sets Oct. 5 Start Date for Incoming CEO Kenneth Gardner-Smith

Reuters
·
Sep 29

Analysts Conflicted on These Healthcare Names: Petmed Express (PETS) and Accendra Health (ACH)

TIPRANKS
·
Sep 21

Accendra Health Names Kenneth Gardner-Smith as Next CEO, Effective Q4 2026

Reuters
·
Sep 17

Accendra Health, - Kenneth Gardner-Smith Expected to Assume CEO Role Early in Q4 2026

THOMSON REUTERS
·
Sep 17

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

THOMSON REUTERS
·
Sep 17

Accendra Health, - Edward Pesicka to Retire from Board When Gardner-Smith Assumes CEO Role

THOMSON REUTERS
·
Sep 17

Avon Technologies: Buy Rating Reiterated on New US$20.3m ACH GEN II Order and Unchanged $2390 Price Target

TIPRANKS
·
Sep 02

Press Release: HashKey Announces 2026 Interim Results

Dow Jones
·
Aug 27

Accendra Health updates capital allocation, CEO succession plans

TIPRANKS
·
Aug 17

Accendra Health Sells First of Two Non-Core Assets, Expects About $45 Million Cash Injection

Reuters
·
Aug 17

Accendra Health - Sale of Two Non-Core Assets to Provide $45 Mln Cash Injection in Q3 and Q4

THOMSON REUTERS
·
Aug 17

Accendra Health - Will not Implement At-the-Market Issuance Program

THOMSON REUTERS
·
Aug 17

Accendra Health - Board Expects to Announce CEO Successor by Mid-September 2026

THOMSON REUTERS
·
Aug 17

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

THOMSON REUTERS
·
Aug 17

Accendra Health Inc : UBS Cuts Target Price to $1.5 from $4.5

THOMSON REUTERS
·
Aug 14